- 1 Maternal B-vitamin and vitamin D status before, during and after pregnancy, and the
- 2 influence of supplementation preconception and during pregnancy: NiPPeR double-blind
- 3 randomized controlled trial (197/200)
- 4 Keith M GODFREY <sup>1,2</sup>; Philip TITCOMBE <sup>1</sup>; Sarah EL-HEIS <sup>1,2</sup>; Benjamin B ALBERT <sup>3</sup>; Elizabeth
- 5 Huiwen THAM <sup>4</sup>; Sheila J BARTON <sup>1</sup>; Timothy KENEALY <sup>3</sup>; Mary Foong-Fong CHONG <sup>4,5</sup>; Heidi
- 6 NIELD<sup>1</sup>; Yap Seng CHONG<sup>4,6,7</sup>; Shiao-Yng CHAN<sup>\* 4,6,7</sup>; Wayne S CUTFIELD<sup>\* 3,8</sup>; NiPPeR Study Group<sup>#</sup>
- 7 \*Joint senior authors

8 #Members of the NiPPeR Study Group authors for the Medline citation are listed in the

- 9 Acknowledgements
- 10 <sup>1</sup> MRC Lifecourse Epidemiology Centre, University of Southampton, University Hospital
- 11 Southampton, Southampton, UK.
- 12 <sup>2</sup> NIHR Southampton Biomedical Research Centre, University of Southampton and University
- 13 Hospital Southampton, NHS Foundation Trust, Southampton, UK.
- <sup>3</sup> Liggins Institute, University of Auckland, Auckland, New Zealand.
- <sup>4</sup> Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research,
- 16 Singapore.
- <sup>5</sup> Saw Swee Hock School of Public Health, National University of Singapore and National
- 18 University Health System
- <sup>6</sup> Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National
- 20 University of Singapore, National University Health System, Singapore.
- <sup>7</sup> Department of Obstetrics and Gynaecology, National University Hospital, Singapore
- <sup>8</sup> A Better Start, New Zealand National Science Challenge, Auckland, New Zealand.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 23 Corresponding author:

24 Professor Keith Godfrey, MRC Lifecourse Epidemiology Centre, University Hospital

- 25 Southampton Mailpoint 95, Southampton, UK.
- 26 Tel: +44 80777624; E-mail: kmg@mrc.soton.ac.uk

#### 27 Source of Funding

28 Public good funding for this investigator-led study is through the UK Medical Research Council (as part of an MRC award to the MRC Lifecourse Epidemiology Unit 29 30 (MC UU 12011/4)); the Singapore National Research Foundation, National Medical 31 Research Council (NMRC, NMRC/TCR/012-NUHS/2014); the National University of Singapore (NUS) and the Agency of Science, Technology and Research (as part of the Growth, 32 33 Development and Metabolism Programme of the Singapore Institute for Clinical Sciences 34 (SICS) (H17/01/a0/005); and as part of Gravida, a New Zealand Government Centre of 35 Research Excellence. Funding for provision of the intervention and control drinks and to cover 36 aspects of the fieldwork for the study has been provided by Société Des Produits Nestlé S.A 37 under a Research Agreement with the University of Southampton, Auckland UniServices Ltd. SICS, National University Hospital Singapore PTE Ltd and NUS. KMG is supported by the 38 39 National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-10042), NIHR 40 Southampton 1000DaysPlus Global Nutrition Research Group (17/63/154) and NIHR 41 Southampton Biomedical Research Center (IS-BRC-1215-20004)), British Heart Foundation 42 (RG/15/17/3174) and the European Union (Erasmus+ Programme ImpENSA 598488-EPP-1-43 2018-1-DE-EPPKA2-CBHE-JP). SYC is supported by a Singapore NMRC Clinician Scientist 44 Awards (NMRC/CSA-INV/0010/2016; MOH-CSAINV19nov-0002). The funders had no role 45 in the data collection and analysis, and the decision to submit for publication. For the purpose 46 of Open Access, the author has applied a Creative Commons Attribution (CC BY) license to any 47 Author Accepted Manuscript version arising from this submission.

#### 48 **Short title** Maternal vitamin and vitamer status preconception to post-partum (65/70 chars)

- 49 Abbreviations list
- 50 AA: anthranilic acid
- 51 BMI: body mass index
- 52 CI: confidence interval
- 53 HAA: hydroxyanthranilic acid
- 54 HIV: human immunodeficiency virus
- 55 HK: 3-hydroxykynurenine
- 56 KA: kynurenic acid
- 57 LC-MS/MS: Liquid chromatography with tandem mass spectrometry
- 58 NiPPeR Trial: Nutritional Intervention Preconception and During Pregnancy to Maintain
- 59 Healthy Glucose Metabolism and Offspring Health trial
- 60 NRES: National Research Ethics Service
- 61 SDS: standard deviation score
- 62 UK: United Kingdom
- 63 US: United States
- 64 XA: 3- xanthurenic acid
- 65
- 66 Clinical trial registration
- 67 1) Date of registration: 15<sup>th</sup> July 2015
- 68 2) Date of initial participant enrollment: 3<sup>rd</sup> August 2015
- 69 3) Clinical trial identification number: NCT02509988; U1111-1171-8056
- 4) URL of the registration site: https://www.clinicaltrials.gov/ct2/show/NCT02509988

- 5) Data sharing information: Individual participant data may be shared upon reasonable
- requests and are subject to approval by the trial management group and the trial consultative
- 73 panel. Application can be made through the corresponding author.
- 74 Word count: Abstract 498 words; Main text 5571 words

#### 75 Abstract

76 Background: Maternal vitamin status preconception and during pregnancy have important 77 consequences for pregnancy outcome and offspring development. Changes in status from 78 preconception to early and late pregnancy and postpartum have been inferred from cross-79 sectional data, with lower pregnancy concentrations often ascribed to plasma volume 80 expansion, but without truly longitudinal data from preconception through pregnancy and post-81 delivery, and sparse data on the influence of supplementation. This study characterized 82 longitudinal patterns of maternal vitamin status from preconception, through early and late 83 pregnancy, to 6-months post-delivery, and determined the influence of supplementation. 84 Methods and Findings: Between 2015-2017, 1729 UK, Singapore and New Zealand women 85 aged 18-38 years planning conception were recruited from the community to a double-blind 86 controlled trial and randomized to a standard (control) or an intervention supplement 87 preconception and throughout pregnancy. Vitamins common to both supplements were folic 88 acid and  $\beta$ -carotene, with the intervention additionally including riboflavin, vitamins B6, B12 89 and D in amounts available in over-the-counter supplements, alongside iron, calcium and 90 iodine (control and intervention) and myo-inositol, probiotics and zinc (intervention only). 91 We measured maternal plasma concentrations of B-vitamins, vitamin D and 92 insufficiency/deficiency markers (homocysteine, hydroxykynurenine-ratio, methylmalonic 93 acid), at recruitment and 1-month after commencing intervention preconception, in early and 94 late pregnancy, and post-delivery (6-months after supplement discontinuation). From all 95 timepoint data, we derived standard deviation scores (SDS) to characterize longitudinal 96 changes in controls and differences between control and intervention participants. At 97 recruitment preconception, significant proportions had marginal or low plasma status for 98 folate (29.2% <13.6 nmol/L), riboflavin (7.5% <5 nmol/L, 82.0% ≤26.5 nmol/L), vitamin B12 (9.1% <221 pmol/L) and vitamin D (48.7% <50 nmol/L). Among controls, plasma 99

5

100 concentrations showed differing longitudinal patterns from preconception; riboflavin fell 101 through early/late pregnancy, 25-hydroxyvitamin D was unchanged in early pregnancy, and 102 vitamin B6 and B12 concentrations declined through pregnancy, becoming >1 SDS lower 103 than baseline by 28 weeks gestation, with 54.2% developing a low late pregnancy vitamin B6 (pyridoxal 5-phosphate <20 nmol/L). Preconception, the control/intervention groups had 104 105 similar baseline vitamin concentrations; 1-month after supplement commencement, plasma 106 concentrations became substantially higher in intervention participants; riboflavin by 0.77 107 SDS (95%CI 0.68-0.87), vitamin B6 1.07 (0.99-1.14), vitamin B12 0.55 (0.46-0.64) and 108 vitamin D 0.51 (0.43-0.60), with the higher levels maintained during pregnancy and marked 109 reduction in insufficiency/deficiency markers (lower homocysteine, hydroxykynurenine-ratio, 110 methylmalonic acid) and the late pregnancy prevalence of vitamin D <50 nmol/L reduced 111 from 35.1% to 8.5%. Plasma vitamin B12 was still higher in the intervention group 6-months 112 post-delivery. 113 Conclusion: Significant proportions of preconception women have marginal or low status of 114 folate, riboflavin, vitamin B12 and vitamin D, and many develop markers of vitamin B6

115 deficiency in late pregnancy. In the absence of supplementation, maternal plasma vitamin

116 concentrations show differing longitudinal patterns from preconception to early and late

117 pregnancy, suggesting plasma volume expansion does not wholly account for lower

118 gestational concentrations. Preconception/pregnancy supplementation in amounts available in

119 over-the-counter supplements substantially reduces the prevalence of deficiency/depletion

120 markers before and during pregnancy, and a higher maternal plasma vitamin B12 was

121 maintained during the recommended lactational period.

122 Keywords: (5-10) micronutrient; supplementation; preconception; pregnancy; postpartum;
123 vitamin B12; vitamin D; B-vitamin; vitamers.

#### 124 Introduction

125 There is an increasing consensus that multiple micronutrient supplementation of pregnant 126 women living in low-middle income countries is beneficial for pregnancy outcomes (1). In 127 high income countries there are few large-scale trials of gestational micronutrient 128 supplementation, resulting in less consensus about the need for individual or multiple 129 micronutrient supplements to be taken. The principal exception relates to preconception and 130 early pregnancy folic acid supplementation and fortification programs, underpinned by the 131 landmark Medical Research Council trial (2). Vitamin D supplementation is also generally 132 recommended, in part based on the recent MAVIDOS trial (3); MAVIDOS used a higher dose 133 of vitamin D than is recommended in many settings (25 µg of cholecalciferol daily from early 134 pregnancy until delivery, vs 10 µg daily recommended in countries such as the UK (4)), which 135 reduced the incidence of infantile atopic eczema in the offspring (5) and improved measures of 136 bone health in the children at age 4 years (6).

137 Recent evidence from animal studies demonstrates that maternal nutritional status prior to conception can have lasting effects on the offspring. This highlights a critical knowledge gap 138 139 with regards to the importance of maternal micronutrient status before and during human 140 pregnancy (7). Evidence from human studies supporting a role for preconception micronutrient 141 status is largely observational, but does point to important implications for pregnancy outcomes 142 and long-term offspring health (8). Examples include the associations of suboptimal vitamin 143 B12 and B6 status with an increased risk of preterm birth (9), and of maternal preconception 144 iodine deficiency with lower child IQ (10).

To date, maternal micronutrient status preconception has largely been inferred from pregnancy data, and truly longitudinal studies describing changes from preconception to early and late pregnancy and postpartum have not previously been conducted. The ongoing significant 148 prevalence of micronutrient insufficiencies among adolescent girls and women of reproductive 149 age in high income countries highlights the importance of documenting such changes (11). 150 Moreover, lower pregnancy concentrations are often ascribed to plasma volume expansion (12, 151 13). without consideration of the longitudinal of pattern measurement or 152 insufficiency/deficiency markers.

153 Human trials of micronutrient supplementation commencing before pregnancy remain 154 relatively few in number; while they have not always shown benefits for maternal and offspring 155 outcomes (14), a recent small trial did, however, report that maternal vitamin B12 156 supplementation from preconception until delivery improved offspring neurodevelopment at 157 age 2 years (15). Development of evidence-based guidelines for micronutrient intake 158 before/during pregnancy is additionally hindered by the paucity of randomized trial data on the 159 change in maternal micronutrient status resulting from preconception and pregnancy 160 supplementation using amounts available in over-the-counter supplements.

161 The NiPPeR trial (16) is a multicenter, double-blind, randomized controlled trial of a nutritional 162 supplement containing micronutrients, myo-inositol and probiotics, whose primary outcome 163 was the maintenance of euglycemia during pregnancy. The trial found no difference in 164 gestational glycemia between study arms, but there was a significant reduction in preterm 165 delivery, preterm pre-labor rupture of membranes and major post-partum hemorrhage with the 166 intervention compared with controls, who received a standard micronutrient supplement (17). 167 Longitudinal blood sampling in the NiPPeR trial provided an opportunity to determine the 168 changes in maternal plasma concentrations of B-vitamins, vitamin D and 169 insufficiency/deficiency markers (homocysteine, hydroxykynurenine-ratio, methylmalonic 170 acid) from preconception, through early and late pregnancy and to 6 months postpartum 171 (notably in the control group), and to examine the influence of maternal supplementation

preconception and during pregnancy on mean concentrations and markers of low vitaminstatus.

#### 174 Subjects and Methods

#### 175 Trial study design

176 The study protocol has been previously published (16). Briefly, women planning a pregnancy 177 were recruited from the community across 3 study sites in the UK, Singapore and New Zealand, 178 between 2015-2017. Trial exclusion criteria were pregnancy/lactation at recruitment, assisted 179 conception (apart from taking clomiphene or letrozole alone), serious food allergy, pre-existing 180 diabetes mellitus, use of hormonal contraception or taking metformin, systemic steroids, 181 anticonvulsants or treatment for HIV, Hepatitis B or C in the past month. With stratification by 182 site and ethnicity to ensure balanced allocation, 1729 women were randomly assigned by an 183 electronic database to receive intervention (n=870) or control (n=859) nutritional supplements 184 from preconception until delivery. Maternal blood samples were collected from 870 185 intervention and 857 control women at preconception (at recruitment and one month after 186 commencing supplementation), and then in early and late pregnancy, and six months post-187 delivery in those who became pregnant. Singleton pregnancies fulfilling the study criteria and 188 reaching 28 weeks' gestation with data on plasma vitamins at baseline and in late pregnancy 189 were achieved in 580 women (Consort diagram shown in Supplementary Figure 1), with 512 190 followed up at 6 months post-delivery.

Intervention and control supplements with similar sensory characteristics and packaged as a powder in sachets were stored at 2-6°C until made up in 250 ml water and taken twice daily. Ingredients common to control and intervention formulations were folic acid 400  $\mu$ g/day, iron 12 mg/day, calcium 150 mg/day, iodine 150  $\mu$ g/day and  $\beta$ -carotene 720  $\mu$ g/day; the intervention additionally included riboflavin 1.8 mg/day, vitamin B6 2.6 mg/day, vitamin B12 196 5.2 µg/day, vitamin D 10 µg/day, zinc 10 mg/day myo-inositol 4 g/day and probiotics 197 (Lactobacillus rhamnosus and Bifidobacterium animalis sp. lactis). Quantities were either UK 198 recommended daily allowances for pregnant women (vitamin D, zinc, folic acid, iodine), 199 minimal amounts for micronutrients linked with potential detrimental effects at higher doses 200 (iron,  $\beta$ -carotene, calcium), or amounts enhanced above those typical in over-the-counter 201 products (vitamins B6, B12, riboflavin) or used in previous trials (myo-inositol, probiotics) 202 (18, 19). Supplements were consumed from preconception following randomization until 203 delivery of the baby. Participants and all study personnel remained blinded to treatment 204 allocation until all pregnancy, delivery and neonatal data had been collected, and analysis of 205 the primary outcome completed. At enrolment, sociodemographic characteristics, menstrual, 206 obstetric and health histories and lifestyle habits were collected via interviewer-administered 207 questionnaires. Weight and height were measured to derive body mass index (BMI). Adherence 208 to the trial formulation ascertained by sachet counting was similar in the control and 209 intervention groups; overall, 80.6% had 80-100% adherence averaged from recruitment to 210 delivery, 15.8% had 60-80% adherence, and only 3.1% adherence below 60%. Women were 211 recommended to refrain from taking other supplements unless advised by their healthcare 212 practitioner (e.g. significant iron deficiency anemia).

The trial was approved by the United Kingdom, Singapore and New Zealand research ethics services (Southampton: Health Research Authority NRES Committee South Central Research Ethics Committee, reference 15/SC/0142l; Singapore: the National Healthcare Group Domain Specific Review Board, reference 2015/00205; New Zealand: the Health and Disability Ethics Committee, reference 15/NTA/21). The relevant regulatory authorities confirmed that the formulation was not an investigational medicinal product. All participants gave written informed consent. Trial oversight and monitoring were provided by an independent data and

safety monitoring committee. This trial was prospectively registered at ClinicalTrials.gov
 NCT02509988, UTN U1111-1171-8056.

#### 222 Vitamin, vitamer and metabolite measurements and status markers

223 EDTA plasma was obtained by centrifugation of peripheral venous blood samples at 1600 g at 4°C for 10 minutes and stored at -80°C for later analyses. Aliquots were available for 224 225 measurement of plasma vitamins and related vitamers/metabolites at the following five time-226 points: preconception at recruitment (n=1721) and 1 month after commencing intervention 227 (n=1454), in early (7-11 weeks' gestation, n=634) and late pregnancy (around 28 weeks' 228 gestation, n=580), and post-delivery, 6 months after discontinuation of supplementation 229 (n=512). Using a targeted method based on liquid chromatography-tandem mass spectrometry 230 (Bevital, Bergen, Norway)(20), we measured plasma concentrations of vitamins present in the 231 control and intervention groups, related vitamers and metabolites that reflect vitamin status: 232 homocysteine (reflecting 1-carbon status and an indicator of folate and B-vitamin deficiency), 233 riboflavin, flavin mononucleotide (reflecting riboflavin status), pyridoxal 5-phosphate (vitamin B6), 3-hydroxykynurenine (HK), kynurenic acid (KA), anthranilic acid (AA), 3- xanthurenic 234 235 acid (XA), hydroxyanthranilic acid (HAA), cystathionine, cysteine, methylmalonic acid and 236 25-hydroxyvitamin D3. Plasma folate and cobalamin (vitamin B12) were measured by 237 microbiological assay, using a microtiter plate format on a robotic workstation employing a 238 chloramphenicol-resistant strain of Lactobacillus casei (folate) and a colistin sulphate-resistant 239 strain of Lactobacillus leichmannii (cobalamin)(Bevital, Bergen, Norway). Detailed quality 240 control data for all analytes has been described previously, documenting coefficients of 241 variation <10% (21). Values below the assay limit of detection were set to half the limit of 242 detection value. Any hemolysis was visually graded from zero to 4+; anthranilic acid, 3-243 hydroxyanthranilic acid and 3-hydroxykynurenine values were set to missing for samples with 244 a hemolysis score  $\geq 2$  (approximately equivalent to Hb 250 mg/dL), and those for folate set to

missing for samples with 4+ hemolysis (approximately equivalent to Hb 1000 mg/dL). Each analyte was checked for outliers (both statistically and clinically), and implausible values were set to missing.

248

As functional markers of vitamin B6 status, we calculated the plasma 3'-hydroxykynurenine 249 250 ratio (HK ratio [HK:KA+AA+XA+HAA], a higher ratio reflecting effects of vitamin B6 insufficiency on tryptophan catabolism), along with the cystathionine/cysteine ratio (a higher 251 252 ratio reflecting effects of vitamin B6 insufficiency on transsulfuration pathway regulation) 253 (22). There is inconsistency in the literature regarding thresholds for vitamin deficiency or 254 insufficiency markers based on plasma measurements: for this study we used plasma folate 255 13.6 nmol/L to define "marginal folate status" (23); homocysteine  $\geq 15 \mu mol/L$  to define "high 256 plasma homocysteine" (24); riboflavin <5 nmol/L (the lower limit of the reference range for 257 the laboratory) and  $\leq 26.5$  nmol/L (the change-point of plasma riboflavin with erythrocyte 258 glutathione reductase activation coefficient (25)) to define low riboflavin and "marginal 259 riboflavin status", respectively; pyridoxal 5-phosphate <20 nmol/L to define low B6 status; 260 cobalamin <148 and <221 pmol/L to define B12 "deficiency" and "depletion", respectively 261 (26); and plasma 25-hydroxyvitamin D3 <50 and <75 nmol/L to define "deficiency" and 262 "insufficiency", respectively (27).

263

#### 264 *Statistics*

The sample size was based on the trial primary outcome of gestational glycemia, as described previously (17). Following log<sub>e</sub> (natural logarithm) transformation where necessary, standardization was applied to all values of each analyte (i.e. ~4902 samples) to derive standard deviation scores (SDS) before being split into separate variables by time-point/visit; the

advantage of this approach is that for each analyte the effect sizes are comparable betweentime-points.

271 For each of the vitamins and related vitamers and metabolites analyses focused on: i) describing 272 the longitudinal changes in maternal concentrations from preconception through pregnancy and 273 to 6 months post-delivery in the control group, ii) the pattern of longitudinal change in the 274 intervention group, and iii) differences in concentration and in sufficiency markers between the 275 control and intervention groups at different time-points, including differences in proportions 276 analyzed using chi-squared tests. Longitudinal plots are shown as means and 95% confidence 277 intervals (CI) in SDS by intervention group on y-axis and time-point/visit on x-axis, with 278 statistical significance considered when the 95%CI did not overlap (two-tailed P<0.05). 279 Differences given in the text are statistically significant unless otherwise stated. Plots and 280 differences in SDS between time-points are based on all available data at each time-point unless 281 otherwise specified. Sensitivity analyses were used to determine whether differences between 282 time-points reflected differences between those who did and did not become pregnant 283 (resulting in differing numbers of participants with preconception, pregnancy and post-delivery 284 measurements), and linear and logistic regression analyses were used to ascertain whether the patterns of longitudinal and control vs intervention group differences were robust to adjustment 285 286 for site and ethnicity (trial randomization stratification factors) and parity (not fully balanced 287 across control and intervention groups and potentially influential on status measurements). 288 Analyses were performed using Stata software v15.1 (StataCorp, College Station, TX, USA).

289

#### 290 Results

291 Characteristics of the participants with preconception data (n=1727), and of those who had 292 baseline analyte data and were followed up at late pregnancy (n=580) are shown in Table 1. 293 Characteristics were balanced across the control and intervention groups, except for somewhat

13

more nulliparity among controls; characteristics for those followed up post-delivery (n=512)
were similar to those with preconception data.

296 Table 2 shows median and interquartile range values for the maternal plasma vitamins and 297 related vitamers/metabolites in their original units at each time-point for each of the control 298 and intervention groups, and Table 3 the percentages of participants below vitamin and 299 vitamer deficiency/insufficiency marker thresholds according to time-point and 300 control/intervention group. The longitudinal changes in maternal concentrations expressed in 301 SDS and proportions with marginal or low status, depletion, deficiency and insufficiency are 302 shown graphically in Figures 1-5. Among all participants at recruitment preconception, 303 significant proportions had marginal or low plasma status for folate (29.2% <13.6 nmol/L), 304 riboflavin (7.5% <5 nmol/L, 82.0% ≤26.5 nmol/L), vitamin B12 (9.1% <221 pmol/L) and

305 vitamin D (48.7% <50 nmol/L); only 1.3% had a low pyridoxal 5-phosphate (<20 nmol/L).

#### 306 *Plasma folate and homocysteine*

307 In the control group (who received 400 µg/day folic acid, as in the intervention group), from 308 preconception baseline to 1-month after supplementation commencement mean maternal 309 plasma folate increased by 0.74 SDS, followed by a further 0.37 SDS increase in early 310 pregnancy, and then declined 0.45 SDS from early to late pregnancy and 0.85 SDS from late 311 pregnancy to 6-months post-delivery, resulting in a post-delivery concentration lower than at 312 preconception baseline (Figure 1a); marginal folate status (<13.6 nmol/L) was present in 28.1% 313 of control group participants at preconception baseline, falling to 4.1% 1-month after 314 supplementation commencement and 1.0% in early pregnancy, before rising to 6.1% in late pregnancy and 31.8% 6-months post-delivery (Figure 1b). The intervention group showed a 315 316 similar longitudinal pattern for plasma folate.

317 Plasma homocysteine concentrations, an indicator of folate and B-vitamin deficiency, in the 318 control group decreased by 0.13 SDS from preconception baseline to 1-month after 319 supplementation commencement, followed by further 0.76 and 0.65 SDS falls in early and late 320 pregnancy, respectively, and then a 1.66 SDS increase 6-months post-delivery, resulting in 321 post-delivery concentration marginally higher than at recruitment (Figure 1c); a high plasma 322 homocysteine  $\geq 15 \mu mol/L$  was present in 0.9% of participants at preconception baseline, 323 falling to 0% in early pregnancy and late pregnancy, and 0.4% 6 months post-delivery. The 324 intervention group showed a similar longitudinal pattern, but plasma homocysteine 325 concentrations were 0.24, 0.41 and 0.40 SDS lower than in the control group 1-month after 326 supplementation commencement and in early and late pregnancy, respectively.

327

#### 328 Plasma riboflavin and flavin mononucleotide

329 Among control group participants (taking a supplement without riboflavin), as expected plasma 330 riboflavin was similar at preconception baseline and 1-month after supplementation 331 commencement, then decreased by 0.24 SDS in early pregnancy, with a further 0.17 SDS 332 decrease in late pregnancy, followed by an increase of 0.43 SDS at 6-months post-delivery, 333 returning to levels similar to those at preconception (Figure 2a). Marginal riboflavin status 334 (≤26.5 nmol/L) was present in 81.1% of control participants at preconception baseline and 335 80.3% 1-month after supplementation commencement, increasing to 85.6% and 92.4% in early 336 and late pregnancy, respectively, before returning to 82.5% 6-months post-delivery 337 (Supplementary Figure 2). Low riboflavin status (<5 nmol/L) in the control group showed a 338 similar longitudinal pattern at the expected lower prevalence (7.3%, 6.2%, 12.5%, 12.8% and 339 4.0%, across the five time-points)(Figure 2b). Compared with the control group, plasma 340 riboflavin concentrations in the intervention group 1-month after supplementation 341 commencement, in early pregnancy and in late pregnancy were higher (by 0.77, 0.76 and 0.65

342 SDS, respectively), with lower prevalences of marginal (56.1%, 66.9% and 81.9%,
343 respectively) and low (0.4%, 0.9% and 2.7%, respectively) riboflavin status.

Plasma flavin mononucleotide, a marker of riboflavin sufficiency, in the control group showed a similar longitudinal pattern to plasma riboflavin but increased by 0.21 SDS from preconception baseline to 1-month after supplementation commencement, before showing a similar decline during pregnancy (Figure 2c). Plasma flavin mononucleotide concentrations were 0.36, 0.47 and 0.33 SDS higher in the intervention vs the control group 1-month after supplementation commencement, in early pregnancy and in late pregnancy, respectively.

350

## 351 Plasma vitamin B6 and B6 insufficiency markers

352 In the control group (taking a supplement without vitamin B6), plasma pyridoxal 5-phosphate 353 was similar at preconception baseline and 1-month after supplementation commencement, then 354 decreased by 0.25 SDS between 1-month after supplementation commencement and early 355 pregnancy, before a substantial further decrease of 1.11 SDS from early pregnancy to late 356 pregnancy, followed by a return to preconception concentrations 6-months post-delivery 357 (Figure 3a); preconception, low pyridoxal 5-phosphate (<20 nmol/L) was present in 0.8% of 358 participants at baseline and 0.1% 1-month after supplementation commencement, increasing 359 to 2.6% in early pregnancy and a steep rise to 54.2% in late pregnancy, before returning to 360 1.2% 6-months post-delivery (Figure 3b). Compared with the control group, the intervention 361 group had higher plasma pyridoxal 5-phosphate concentrations at 1-month after 362 supplementation commencement, and in early and late pregnancy, by 1.07, 0.95 and 0.84 SDS, respectively. 363

Among control participants, the plasma HK ratio was unchanged from the preconception baseline through 1-month after supplementation commencement and in early pregnancy, but then rose sharply by 1.03 SDS between early and late pregnancy, reflecting reduced activity of

367 vitamin B6 dependent pathways; between late pregnancy and 6-months post-delivery the HK 368 ratio fell by 0.67 SDS, to a level that was higher than the preconception baseline (Figure 3c). 369 Compared with the control group, in the intervention group plasma HK ratio was lower at 1-370 month after supplementation commencement, in early pregnancy and in late pregnancy, by 371 0.51, 0.63 and 0.29 SDS, respectively. In the control group, the plasma cystathionine/cysteine 372 ratio increased from preconception baseline to 1-month after supplementation commencement, 373 decreasing to a level slightly lower than baseline in early pregnancy, followed by a 1.36 SDS 374 rise between early and late pregnancy, and then a fall 6-months post-delivery to a level higher 375 than the preconception baseline (Supplementary Figure 2). Similar to the HK ratio, compared 376 with the control group, the plasma cystathionine/cysteine ratio was lower in the intervention 377 group 1-month after supplementation commencement, in early pregnancy and in late 378 pregnancy, by 0.35, 0.37 and 0.23 SDS, respectively.

379

#### 380 Plasma vitamin B12 and methylmalonic acid

381 In the control group (taking a supplement without vitamin B12), plasma cobalamin was similar at preconception baseline and 1-month after supplementation commencement, then decreased 382 383 by 0.41 SDS in early pregnancy, further decreased by 0.88 SDS in late pregnancy, then 384 returning to baseline preconception concentrations 6-months post-delivery (Figure 4a); 385 preconception, vitamin B12 deficiency (<148 pmol/L) was present in 0.6% of participants at 386 baseline and 1-month after supplementation commencement, increasing to 1.6% and 11.1% in 387 early and late pregnancy, respectively, before returning to 0.8% 6-months post-delivery 388 (Supplementary Figure 4). Vitamin B12 depletion (<221 pmol/L) in the control group showed 389 a similar longitudinal pattern at the expected higher prevalence (7.5%, 7.0%, 18.1%, 55.2%) 390 and 12.4%, across the five time-points) (Figure 4b). Compared with the control group, in the 391 intervention group plasma cobalamin concentrations 1-month after supplementation

392 commencement, in early pregnancy and in late pregnancy were higher (by 0.55, 0.75 and 0.79) 393 SDS, respectively), with lower prevalences of vitamin B12 deficiency (0%, 0.3% and 4.8%, 394 respectively), and of vitamin B12 depletion (2.4%, 3.7% and 16.7%, respectively). Notably, 395 plasma vitamin B12 was 0.3 SDS higher in the intervention group than the control group 6-396 months post-delivery, with a lower prevalence of vitamin B12 depletion (5.4% vs 12.4%). 397 Plasma methylmalonic acid, a metabolic indicator of vitamin B12 insufficiency, in the control 398 group increased by 0.29 SDS from preconception baseline to 1-month after supplementation 399 commencement, then decreasing by 0.45 SDS in early pregnancy before increasing 0.39 SDS 400 in late pregnancy and staying at a similar level 6-months post-delivery, 0.31 SDS above the 401 original preconception baseline value (Figure 2c). Plasma methylmalonic acid concentrations 402 in the intervention group were similar to those in the control group 1-month after 403 supplementation commencement, but 0.21 and 0.49 SDS lower in early pregnancy and in late 404 pregnancy, respectively; 6-months post-delivery there was a 0.17 SDS lower concentration in 405 the intervention group (P=0.05).

406

#### 407 Plasma 25-hydroxyvitamin D

408 In the control group, plasma 25-hydroxyvitamin D changed little from preconception baseline 409 to 1-month after supplementation commencement and early pregnancy, then increased by 0.28 410 SDS between early and late pregnancy, remaining similar to late pregnancy concentrations 6-411 months post-delivery (Figure 5a). Vitamin D deficiency <50 nmol/L in the control group 412 showed a similar longitudinal pattern, with high prevalences at preconception baseline, 1-413 month after supplementation commencement and in early pregnancy (47.7%, 47.5% and 414 43.0%, respectively), and rather lower prevalences in late pregnancy (35.1%) and 6-months 415 post-delivery (30.7%)(Figure 5b); vitamin D insufficiency <75 nmol/L showed a similar 416 longitudinal pattern at high prevalence levels (85.7%, 85.1%, 82.3%, 64.6%, and 70.5%, across

the five time-points)(Figure 5c). Compared with the control group, in the intervention group plasma 25-hydroxyvitamin D concentrations 1-month after supplementation commencement, in early pregnancy and in late pregnancy were higher (by 0.51, 0.63 and 0.89 SDS, respectively), with prevalences of vitamin D deficiency (22.0%, 12.2% and 8.5%, respectively) and insufficiency (78.2%, 65.7% and 27.3%, respectively) that were substantially lower than the control group; 6-months post-delivery plasma 25-hydroxyvitamin D concentrations were similar in the intervention and control groups (Figures 5b, 5c).

424

#### 425 Sensitivity analyses

In sensitivity analyses of participants with complete preconception, pregnancy and postdelivery data the patterns described above for each of the vitamins and vitamers/metabolites were confirmed as little different, with no substantive differences from the analyses of all participants with measurements at any time-point (Supplementary Table 1). Further sensitivity analyses showed that the patterns of longitudinal and control vs intervention group differences were robust to adjustment for site, ethnicity and parity.

432

#### 433 Discussion

434 Among UK, Singapore and New Zealand women attempting to become pregnant in this multi-435 center randomized controlled trial, significant proportions had marginal or low status of folate, 436 riboflavin, vitamin B12 and vitamin D at recruitment preconception, and a high proportion 437 developed markers of functional vitamin B6 deficiency in late pregnancy despite a small 438 proportion having a low vitamin B6 status preconception. Plasma concentrations for the above 439 vitamins, related vitamers and metabolic insufficiency markers showed differing patterns of 440 change from preconception to pregnancy and 6-months post-delivery. A formulation enriched 441 with micronutrients in amounts available in over-the-counter supplements commenced

442 preconception and continued throughout pregnancy substantially increased plasma folate, 443 riboflavin and vitamins B6, B12 and D concentrations and reduced the prevalence of their 444 deficiency/depletion markers before and during pregnancy, with a persisting benefit of higher 445 plasma vitamin B12 to 6-months post-delivery.

446 As routinely recommended for preconception and pregnancy, supplementation with 400 µg 447 folic acid daily in both the control and intervention groups raised plasma folate by >1 SDS 448 from baseline to early pregnancy and reduced the prevalence of marginal folate status from 449 28.1% at baseline to 1.0% in early pregnancy. Our findings show that even with 400 µg, the 450 lowest commonly marketed dose, there are appreciable improvements in folate status after 1 451 month and continued improvement into pregnancy. Plasma homocysteine in the control group 452 fell substantially from preconception baseline to early pregnancy and again from early to late 453 pregnancy, with greater falls in plasma homocysteine in the intervention group taking a 454 supplement containing other micronutrients. While some have proposed that vitamin B6, 455 riboflavin and zinc might reduce homocysteine, there are data pointing away from this (28, 29). 456 One previous review concluded that dietary folic acid reduced homocysteine levels by 25% 457 and vitamin B12 produced an additional 7% reduction in blood homocysteine levels, whereas 458 vitamin B6 had no significant additive effect (30). Our findings support effects of both the folic 459 acid and the other micronutrients in the intervention group acting to improve 1-carbon status 460 and reduce plasma homocysteine, with potential benefit for pregnancy and offspring outcomes 461 (31).

462

In the control group, plasma riboflavin and flavin mononucleotide showed modest falls from preconception to early pregnancy, and again from early to late pregnancy. We considered measuring the gold standard erythrocyte glutathione reductase activation coefficient as a specific riboflavin deficiency marker, but resource to support this could not be secured.

467 Detailed studies have identified  $\leq 26.5$  nmol/L as the change-point of plasma riboflavin below 468 which the erythrocyte glutathione reductase activation coefficient becomes elevated (25). 469 Using this 26.5 nmol/L threshold, 82.0% of participants had a "marginal riboflavin status" at 470 baseline, with 7.5% having a riboflavin concentration <5 nmol/L. In the intervention group, 471 supplementation with 1.8 mg/day riboflavin, as in many prenatal supplements, substantially 472 raised plasma riboflavin and reduced the prevalences of marginal and low riboflavin status 473 before and during pregnancy. The implications of marginal or low riboflavin status before and 474 during pregnancy have rarely been studied, but in a large cohort of pregnant women in Ireland 475 and Northern Ireland biomarker analysis showed that 68% had low or deficient riboflavin 476 status, which was associated with a higher risk of anaemia during pregnancy (32).

477 Plasma pyridoxal 5-phosphate in the control group showed a modest fall from preconception 478 to early pregnancy, but then a substantial fall from early to late pregnancy, accompanied by a 479 sharp rise in plasma HK and cystathionine: cysteine ratios, reflecting impairment of vitamin B6 480 dependent pathways in late pregnancy. For vitamin B6, pyridoxal 5-phosphate is the most 481 commonly used status marker (33); the HK ratio, composed of HK and the four kynurenines 482 that are products of the pyridoxal 5-phosphate dependent enzymes, kynurenine transaminase 483 and kynureninase has been developed as a marker of tryptophan catabolism regulation by 484 vitamin B6 that rises in B6 deficiency (33, 34). Evaluation has also found that the ratio of 485 cystathionine:cysteine (transsulfuration pathway regulation) has merit as a B6 intake marker, 486 while being more subject to other influences than the HK ratio (22). The marked late gestation 487 rises in HK ratio is consistent with evidence of kynurenine pathway enzyme inhibition by the 488 more than 10-fold physiological increase in estrogen with advancing gestation from mid to late 489 pregnancy (35, 36). This late gestation inhibition of the kynurenine pathway may be partly 490 physiological but nonetheless has implications for B6 nutrient supply to the fetus and potential 491 impacts on later offspring health. Notably, there is increasing evidence linking childhood

492 kynurenine pathway perturbations with metabolic health risk (37). In our study, the 493 intervention, providing 2.6 mg vitamin B6 daily, substantially increased plasma pyridoxal 5-494 phosphate levels and lowered the plasma HK ratio in late pregnancy, with a lowering of the 495 cvstathionine:cvsteine ratio also supporting a lesser impairment of vitamin B6 dependent 496 pathways. While the US Institute of Medicine Recommended Dietary Allowance for vitamin 497 B6 in pregnancy is 1.9 mg/day (38), European Community recommendations for pregnancy 498 are that vitamin B6 supplements of 2.5-4 mg/day are required to maintain the plasma 499 concentration of vitamin B6 at pre-pregnancy levels (39).

500

501 In the control group plasma vitamin B12 showed modest falls from preconception to early 502 pregnancy, and a larger fall from early to late pregnancy, accompanied by increases in the late 503 pregnancy prevalences of vitamin B12 deficiency and depletion (11.1% and 55.2%, 504 respectively) and a rise in plasma methylmalonic acid as a marker of vitamin B12 insufficiency; 505 this is in keeping with previous reports of raised vitamin B12 deficiency markers in late 506 pregnancy (40). Supplementation with 5.2 µg/day vitamin B12 led to higher plasma cobalamin 507 and lower methylmalonic acid during pregnancy in the intervention group. Recommended 508 daily allowance amounts for vitamin B12 vary internationally. Meta-analysis of randomised 509 trials in non-pregnant individuals concluded that a doubling of vitamin B12 intake increases 510 vitamin B12 concentrations by 14%, with a consistent benefit of amounts similar to the 5.2 511  $\mu g/day$  used in this trial (41), whereas smaller amounts are less consistent in their effect on B12 512 status (42). Systematic review has linked lower maternal vitamin B12 status with a variety of 513 adverse pregnancy outcomes, including a higher risk of neural tube defects, recurrent 514 pregnancy losses, gestational diabetes, pre-eclampsia, and lower birth weight (43), and meta-515 analysis has shown that lower plasma concentrations associate with a higher risk of preterm 516 delivery (44). Lower maternal concentrations are also associated with adverse cardiometabolic 517 and neurocognitive outcomes in the offspring (43, 45). While randomised trials of vitamin B12 518 supplementation in pregnancy have been inconclusive in relation to an effect on birth weight 519 they support a beneficial effect on offspring neurocognitive development (43). In our study 520 maternal plasma cobalamin was still higher in the intervention group post-delivery, 6-months 521 after discontinuation of supplementation, most likely reflecting repletion of hepatic stores. It is 522 likely this would increase breast milk vitamin B12 supply to the infant given the strong 523 correlation between maternal plasma and breast milk concentrations (46). This is potentially of 524 importance as post-delivery maternal vitamin B12 supplementation with the low doses found 525 in most over-the-counter supplements (1 to 10  $\mu$ g/day) are widely thought to result in only 526 modest increases in human milk levels (47).

527 Plasma 25-hydroxyvitamin D in the control group taking a supplement without vitamin D was 528 remarkably unchanged from preconception baseline to early pregnancy, then increased 529 modestly between early and late pregnancy, with high prevalences of vitamin D deficiency and 530 insufficiency at baseline preconception (47.7% and 85.7%, respectively) and through 531 pregnancy. Supplementation with 10 µg of vitamin D in the intervention group led to 532 progressive increases in plasma 25-hydroxyvitamin D and a substantial reduction in the 533 prevalences of vitamin D deficiency and insufficiency during pregnancy (e.g. 8.5% and 27.3%) 534 in late pregnancy, respectively vs 35.1% and 64.6% in the control group). The dose of vitamin 535 D recommended for routine use in pregnancy varies internationally, with some advocating 100 536 µg daily or higher (48), while the World Health Organization/Food and Agriculture 537 Organization of the United Nations recommends 5 µg daily (49); in the UK it is recommended 538 that pregnant women should consider taking a supplement containing 10 µg between 539 September and March (4). In the MAVIDOS randomised trial supplementation 25 µg of 540 vitamin D daily from 14 weeks gestation until delivery lowered the incidence of infantile atopic 541 eczema (5) and increased childhood areal bone mineral density in the offspring (6). Vitamin D

is stored in adipose tissue and our trial suggests that low dose (10 µg) supplementation over a
long period starting preconception can support improved gestational vitamin D status.

544 The finding of significant prevalences of vitamin insufficiencies in women living in high 545 income countries who are attempting to become pregnant is a serious concern. This is 546 particularly the case given increasing advocacy to reduce meat and dairy intakes to achieve 547 "net-zero" carbon emissions, as these foods are micronutrient dense and support nutritional 548 adequacy (50, 51). The high prevalence of vitamin insufficiencies and increasing move towards 549 plant-based diets, which lack vitamin B12 and are low in other micronutrients, is likely to result 550 in more women resorting to over-the-counter supplements. Currently, over-the-counter 551 supplements intended for preconception and pregnancy show considerable variation in which 552 micronutrients they include and in the amounts of those included. As the amounts incorporated 553 into the intervention supplement were comparable to those available in over-the-counter 554 supplements, the effects we report on vitamin status before and during pregnancy are 555 generalizable and fill an important gap in the literature.

556 To date changes in vitamin status from preconception to early and late pregnancy and 557 postpartum have largely been inferred from cross-sectional data, with lower concentrations 558 during pregnancy often ascribed to plasma volume expansion (12, 13). Our findings show 559 however that the magnitude and pattern of change varies between nutrients, inconsistent with an effect wholly due to physiological hemodilution, and that markers of functional B6 (HK 560 561 ratio) and B12 (methylmalonic acid) insufficiency increase during pregnancy. Variations between individual vitamins in maternal metabolism, intake, renal loss and feto-placental 562 563 demands during pregnancy may all contribute to these varying patterns. Our randomized trial 564 has shown for the first time that preconception and pregnancy supplementation including 565 riboflavin, folic acid and vitamins B6, B12 and D in amounts available in over-the-counter

566 supplements can contribute to the reduction in vitamin insufficiencies during the 567 preconception, pregnancy and lactational periods. The potential benefits for pregnancy 568 outcome and offspring health remain to be characterized.

569 Strengths and Limitations

570 Strengths of our study include longitudinal plasma samples from preconception through 571 pregnancy to 6-months post-delivery, an interventional component, a relatively large sample 572 size and inclusion of multiple ethnic groups. The robust conduct of this double-blind RCT, 573 which included prospectively collected data and minimization of residual confounding through 574 randomization, with external oversight by an independent data monitoring and trial steering 575 committee, is a strength. Over 96% of women showed good adherence defined a priori as 576 supplement intake greater than 60% averaged from recruitment to delivery. Even though 577 recruitment occurred across three different countries with inclusion of multiple ethnicities, generalizability to the global population is limited by the lack of African and Amerindian 578 579 women in particular. The recruited population were generally healthy and well-nourished, yet 580 evidence recognized as indicating micronutrient insufficiency was widespread; whether some 581 changes represent a normal physiological change in pregnancy or a true insufficiency awaits 582 characterization of relations with pregnancy and offspring outcomes. Another strength is the use of an accredited clinical laboratory for analyses of clinical biomarkers. In this study the 583 584 entire sample set was analyzed for tryptophan and kynurenine metabolites in a single laboratory 585 by a targeted LC-MS/MS method including authentic labelled internal standards for each 586 analyte providing high analytical precision. The analyses were carried out in continuous sample 587 batches, with small variability between each batch. Finally, standardized scores were used in 588 the regression models so that the strength of associations were comparable.

589 Conclusions

590 Significant proportions of preconception women living in high income countries have marginal 591 or low status of folate, riboflavin, vitamin B12 and vitamin D, and many develop markers of 592 vitamin B6 deficiency in late pregnancy. In the absence of the intervention supplement, 593 maternal plasma concentrations show differing longitudinal patterns between vitamins from 594 preconception to early and late pregnancy, inconsistent with plasma volume expansion wholly 595 accounting for lower gestational concentrations, and markers of functional B6 and B12 596 insufficiency increase during pregnancy. Preconception and pregnancy supplementation in 597 amounts available in over-the-counter supplements substantially reduced the prevalence of 598 deficiency/depletion markers before and during pregnancy, and a higher maternal plasma 599 vitamin B12 was maintained during the recommended lactational period. In the setting of 600 increasing advocacy for more diets that are likely to be less nutrient dense, the findings suggest 601 a need to reappraise dietary recommendations for preconception and pregnancy and to consider 602 further the role of multiple micronutrient supplements in women living in higher income 603 countries.

#### 604 Author Contributions:

605 Keith M Godfrey: Conceptualization, Methodology, Investigation, Writing review and 606 editing, Supervision, Project administration, Funding acquisition. Philip Titcombe: Validation, Analysis, Data curation, Writing original draft, Visualization; Sarah El-Heis: 607 608 Methodology, Investigation, Writing review and editing; Benjamin Albert: Investigation, 609 Writing review and editing; Elizabeth Tham: Investigation, Writing review and editing; 610 Sheila Barton: Methodology, Validation, Analysis, Resources, Data curation, Writing review 611 and editing; Timothy Kenealy: Investigation, Writing review and editing; Heidi Nield: 612 Resources, Project administration, Writing review and editing; Mary Foong-Fong Chong: 613 Writing review and editing; Yap Seng Chong: Conceptualization, Methodology, Writing review and editing, Supervision, Funding acquisition; Shiao-Yng Chan: Conceptualization, 614

- 615 Methodology, Validation, Analysis, Investigation, Writing original draft, Visualization,
- 616 Supervision, Project administration; Wayne Cutfield: Methodology, Investigation, Writing
- 617 review and editing, Supervision, Project administration;
- 618
- 619 Acknowledgements
- 620 The NiPPeR Study Group authors for the Medline citation comprises the following:
- 621 National University Hospital, Singapore: Julie Ann Guiao Castro (julie castro@nuhs.edu.sg),
- 622 Wendy Sim (sin nie sim@nuhs.edu.sg), Gladys Woon (gladys woon@nuhs.edu.sg), Hsin
- 623 Fang Chang (<u>hsin\_fang\_chang@nuhs.edu.sg</u>)
- 624 Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research,
- 625 Singapore: Gernalia Satianegara (gernalia\_satianegara@sics.a-star.edu.sg), Karen ML Tan
- 626 (karen\_tan@sics.a-star.edu.sg), Vicky Tay (<u>Vicky\_tay@sics.a-star.edu.sg</u>), Jui-Tsung Wong
- 627 (<u>csd3589@yahoo.com</u>)
- 628 MRC Lifecourse Epidemiology Centre, University of Southampton, UK: Paula Costello
- 629 (pc@mrc.soton.ac.uk), Vanessa Cox (vac@mrc.soton.ac.uk), Nicholas C Harvey
  630 (nch@mrc.soton.ac.uk), Sevasti Galani (sevasti.galani@ucl.ac.uk)
- 631 Liggins Institute, University of Auckland, New Zealand: Mary Cavanagh
- 632 (m.cavanagh@auckland.ac.nz), Judith Hammond (j.hammond@auckland.ac.nz), Mark H.
- 633 Vickers (<u>m.vickers@auckland.ac.nz</u>)
- 634 Société Des Produits Nestlé S.A.: Aristea Binea (aristea.binia@rdls.nestle.com), Irma Silva-
- 635 Zolezzi(<u>Irma.SilvaZolezzi@nestle.com</u>), Chiara Nembrini
- 636 (<u>Chiara.Nembrini@rdls.nestle.com</u>)
- 637 We thank the participants and their families for their enthusiastic involvement in the study; the
- 638 study research staff and hospital clinical staff at participating centers, and operational support

639	staff for their contributions to the trial; and the members of the Independent Data Monitoring
640	and Safety Committee for their contributions and oversight of the conduct of the trial.

#### 641 Conflicts of Interest

SC, PNB, YSC, WC and KG report grants from Société Des Produits Nestlé S.A. during the 642 conduct of the study, and are co-inventors on patent filings by Nestlé S.A. relating to the 643 NiPPeR intervention or its components. SC, SB, PT, WC and KG are part of an academic 644 645 consortium that has received grants from Abbott Nutrition, Nestlé S.A., Danone and 646 Benevolent AI Bio Ltd outside the submitted work. SC has received reimbursement and 647 honoraria into her research funds from Nestlé S.A. for speaking at a conference. KG has 648 received reimbursement for speaking at conferences sponsored by companies selling 649 nutritional products. All other authors declare no competing interests.

### 650 References

Keats EC, Haider BA, Tam E, Bhutta ZA. Multiple-micronutrient supplementation for
 women during pregnancy. The Cochrane database of systematic reviews. 2019;3(3):Cd004905.
 Prevention of neural tube defects: results of the Medical Research Council Vitamin
 Study. MRC Vitamin Study Research Group. Lancet (London, England). 1991;338(8760):131 7.

Cooper C, Harvey NC, Bishop NJ, Kennedy S, Papageorghiou AT, Schoenmakers I, et
al. Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a
multicentre, double-blind, randomised placebo-controlled trial. The lancet Diabetes &
endocrinology. 2016;4(5):393-402.

- 660 4. NHS. [Available from: <u>https://www.nhs.uk/pregnancy/keeping-well/vitamins-</u> 661 <u>supplements-and-nutrition/</u>.
- 5. El-Heis S, D'Angelo S, Curtis EM, Healy E, Moon RJ, Crozier SR, et al. Maternal
  antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of
  life: evidence from a randomized controlled trial. The British journal of dermatology.
  2022;187(5):659-66.
- 6. Curtis EM, Moon RJ, D'Angelo S, Crozier SR, Bishop NJ, Gopal-Kothandapani JS, et
  al. Pregnancy Vitamin D Supplementation and Childhood Bone Mass at Age 4 Years: Findings
  From the Maternal Vitamin D Osteoporosis Study (MAVIDOS) Randomized Controlled Trial.
  JBMR plus. 2022;6(7):e10651.
- Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et
  al. Origins of lifetime health around the time of conception: causes and consequences. Lancet
  (London, England). 2018;391(10132):1842-52.
- 8. Stephenson J, Heslehurst N, Hall J, Schoenaker D, Hutchinson J, Cade JE, et al. Before
  the beginning: nutrition and lifestyle in the preconception period and its importance for future
  health. Lancet (London, England). 2018;391(10132):1830-41.
- 676 9. Ronnenberg AG, Goldman MB, Chen D, Aitken IW, Willett WC, Selhub J, et al.
  677 Preconception homocysteine and B vitamin status and birth outcomes in Chinese women. Am
  678 J Clin Nutr. 2002;76(6):1385-91.
- Robinson SM, Crozier SR, Miles EA, Gale CR, Calder PC, Cooper C, et al.
  Preconception Maternal Iodine Status Is Positively Associated with IQ but Not with Measures
  of Executive Function in Childhood. The Journal of nutrition. 2018;148(6):959-66.
- 582 11. Sukumar N, Adaikalakoteswari A, Venkataraman H, Maheswaran H, Saravanan P.
  583 Vitamin B<sub&gt;12&lt;/sub&gt; status in women of childbearing age in the UK and its
  584 relationship with national nutrient intake guidelines: results from two National Diet and
  585 Nutrition Surveys. BMJ Open. 2016;6(8):e011247.
- Aguree S, Gernand AD. Plasma volume expansion across healthy pregnancy: a
  systematic review and meta-analysis of longitudinal studies. BMC pregnancy and childbirth.
  2019;19(1):508.
- Hall MH, Pirani BB, Campbell D. The cause of the fall in serum folate in normal
  pregnancy. British journal of obstetrics and gynaecology. 1976;83(2):132-6.
- 691 14. Sahariah SA, Gandhi M, Chopra H, Kehoe SH, Johnson MJ, di Gravio C, et al. Body
- 692 Composition and Cardiometabolic Risk Markers in Children of Women who Took Part in a
  693 Randomized Controlled Trial of a Preconceptional Nutritional Intervention in Mumbai, India.
  694 The Journal of nutrition. 2022;152(4):1070-81.
- 695 15. D'Souza N, Behere RV, Patni B, Deshpande M, Bhat D, Bhalerao A, et al. Pre-696 conceptional Maternal Vitamin B12 Supplementation Improves Offspring Neurodevelopment
- at 2 Years of Age: PRIYA Trial. Frontiers in pediatrics. 2021;9:755977.

698 16. Godfrey KM, Cutfield W, Chan SY, Baker PN, Chong YS, NiPPeR Study Group.
699 Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose
700 Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial.
701 Trials. 2017;18(1):131.

702 17. Godfrey KM, Barton SJ, El-Heis S, Kenealy T, Nield H, Baker PN, et al. Myo-Inositol,
703 Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in
704 Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial.
705 Diabetes care. 2021;44(5):1091-9.

The ang H, Lv Y, Li Z, Sun L, Guo W. The efficacy of myo-inositol supplementation to
 prevent gestational diabetes onset: a meta-analysis of randomized controlled trials. The journal

- of maternal-fetal & neonatal medicine : the official journal of the European Association of
   Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International
   Society of Perinatal Obstet. 2019;32(13):2249-55.
- 19. Laitinen K, Poussa T, Isolauri E. Probiotics and dietary counselling contribute to
  glucose regulation during and after pregnancy: a randomised controlled trial. The British
  journal of nutrition. 2009;101(11):1679-87.
- Midttun Ø, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to Bvitamin status, tryptophan metabolism and inflammation in human plasma by liquid
  chromatography/tandem mass spectrometry. Rapid communications in mass spectrometry :
  RCM. 2009;23(9):1371-9.
- 21. Ulvik A, McCann A, Midttun Ø, Meyer K, Godfrey KM, Ueland PM. Quantifying
  Precision Loss in Targeted Metabolomics Based on Mass Spectrometry and Nonmatching
  Internal Standards. Analytical chemistry. 2021;93(21):7616-24.
- Clasen JL, Heath AK, Van Puyvelde H, Huybrechts I, Park JY, Ferrari P, et al. A
  comparison of complementary measures of vitamin B6 status, function, and metabolism in the
  European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr.
  2021;114(1):338-47.
- Oner N, Vatansever U, Karasalihoğlu S, Ekuklu G, Celtik C, Biner B. The prevalence
  of folic acid deficiency among adolescent girls living in Edirne, Turkey. The Journal of
  adolescent health : official publication of the Society for Adolescent Medicine.
  2006;38(5):599-606.
- Moretti R, Caruso P. The Controversial Role of Homocysteine in Neurology: From
  Labs to Clinical Practice. International journal of molecular sciences. 2019;20(1).
- Tan A, Zubair M, Ho C-l, McAnena L, McNulty H, Ward M, et al. Plasma riboflavin
  concentration as novel indicator for vitamin-B2 status assessment: suggested cutoffs and its
  association with vitamin-B6 status in women. Proceedings of the Nutrition Society.
  2020;79(OCE2):E658.
- Simpson JL, Bailey LB, Pietrzik K, Shane B, Holzgreve W. Micronutrients and women
  of reproductive potential: required dietary intake and consequences of dietary deficiency or
  excess. Part I--Folate, Vitamin B12, Vitamin B6. The journal of maternal-fetal & neonatal
  medicine : the official journal of the European Association of Perinatal Medicine, the
  Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal
  Obstet. 2010;23(12):1323-43.
- Z7. Loo EXL, Tham EH, Phang KW, Goh A, Teoh OH, Chong YS, et al. Associations
  between maternal vitamin D levels during pregnancy and allergic outcomes in the offspring in
  the first 5 years of life. Pediatric allergy and immunology : official publication of the European
  Society of Pediatric Allergy and Immunology. 2019;30(1):117-22.
- 745 28. Ducker GS, Rabinowitz JD. One-Carbon Metabolism in Health and Disease. Cell metabolism. 2017;25(1):27-42.

Ducros V, Andriollo-Sanchez M, Arnaud J, Meunier N, Laporte F, Hininger-Favier I,
et al. Zinc supplementation does not alter plasma homocysteine, vitamin B12 and red blood
cell folate concentrations in French elderly subjects. Journal of trace elements in medicine and
biology : organ of the Society for Minerals and Trace Elements (GMS). 2009;23(1):15-20.

751 30. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the 752 randomized trials of homocysteine-lowering vitamin supplements. Seminars in thrombosis and 753 hemostasis. 2000;26(3):341-8.

Rojas-Gómez A, Solé-Navais P, Cavallé-Busquets P, Ornosa-Martin G, Grifoll C,
Ramos-Rodriguez C, et al. Pregnancy homocysteine and cobalamin status predict childhood
metabolic health in the offspring. Pediatric research. 2022.

- Duffy B, Pentieva K, Ward M, Psara E, O'Sullivan E, Horrigan G, et al. Impact of
  riboflavin status on haemoglobin and risk of anaemia in pregnancy. Proceedings of the
  Nutrition Society. 2021;80(OCE1):E45.
- 33. Ueland PM, Ulvik A, Rios-Avila L, Midttun Ø, Gregory JF. Direct and Functional
  Biomarkers of Vitamin B6 Status. Annual review of nutrition. 2015;35:33-70.
- 34. Ulvik A, Midttun Ø, McCann A, Meyer K, Tell G, Nygård O, et al. Tryptophan
  catabolites as metabolic markers of vitamin B-6 status evaluated in cohorts of healthy adults
  and cardiovascular patients. Am J Clin Nutr. 2020;111(1):178-86.
- Jayawickrama GS, Nematollahi A, Sun G, Gorrell MD, Church WB. Inhibition of
  human kynurenine aminotransferase isozymes by estrogen and its derivatives. Sci Rep.
  2017;7(1):17559.
- Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies:
  a reference table for clinicians. Obstetrics and gynecology. 2009;114(6):1326-31.
- Tan KM, Tint MT, Kothandaraman N, Yap F, Godfrey KM, Lee YS, et al. Association
  of plasma kynurenine pathway metabolite concentrations with metabolic health risk in
  prepubertal Asian children. International journal of obesity (2005). 2022;46(6):1128-37.
- 38. Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary
  Reference I, its Panel on Folate OBV, Choline. The National Academies Collection: Reports
  funded by National Institutes of Health. Dietary Reference Intakes for Thiamin, Riboflavin,
  Niacin, Vitamin B(6), Folate, Vitamin B(12), Pantothenic Acid, Biotin, and Choline.
  Washington (DC): National Academies Press (US)
- 778 Copyright © 1998, National Academy of Sciences.; 1998.
- 779 39. Proposed nutrient and energy intakes for the European community: a report of the
  780 Scientific Committee for Food of the European community. Nutrition reviews.
  781 1993;51(7):209-12.
- 40. Greibe E, Andreasen BH, Lildballe DL, Morkbak AL, Hvas AM, Nexo E. Uptake of
  cobalamin and markers of cobalamin status: a longitudinal study of healthy pregnant women.
  Clinical chemistry and laboratory medicine. 2011;49(11):1877-82.
- 785 41. Dullemeijer C, Souverein OW, Doets EL, van der Voet H, van Wijngaarden JP, de Boer
  786 WJ, et al. Systematic review with dose-response meta-analyses between vitamin B-12 intake
- and European Micronutrient Recommendations Aligned's prioritized biomarkers of vitamin B-
- 12 including randomized controlled trials and observational studies in adults and elderly
   persons. Am J Clin Nutr. 2013;97(2):390-402.
- 42. Sanchez H, Albala C, Lera L, Dangour AD, Uauy R. Effectiveness of the National
  Program of Complementary Feeding for older adults in Chile on vitamin B12 status in older
  adults; secondary outcome analysis from the CENEX Study (ISRCTN48153354). Nutrition
  journal. 2013;12:124.
- 43. Behere RV, Deshmukh AS, Otiv S, Gupte MD, Yajnik CS. Maternal Vitamin B12
  Status During Pregnancy and Its Association With Outcomes of Pregnancy and Health of the

- 796 Offspring: A Systematic Review and Implications for Policy in India. Frontiers in 797 endocrinology. 2021;12:619176.
- 44. Rogne T, Tielemans MJ, Chong MF, Yajnik CS, Krishnaveni GV, Poston L, et al.
  Associations of Maternal Vitamin B12 Concentration in Pregnancy With the Risks of Preterm
  Birth and Low Birth Weight: A Systematic Review and Meta-Analysis of Individual
  Participant Data. American journal of epidemiology. 2017;185(3):212-23.
- 45. Lai JS, Mohamad Ayob MN, Cai S, Quah PL, Gluckman PD, Shek LP, et al. Maternal plasma vitamin B12 concentrations during pregnancy and infant cognitive outcomes at 2 years
- 804 of age. The British journal of nutrition. 2019;121(11):1303-12.
- Bae S, West AA, Yan J, Jiang X, Perry CA, Malysheva O, et al. Vitamin B-12 Status
  Differs among Pregnant, Lactating, and Control Women with Equivalent Nutrient Intakes. The
  Journal of nutrition. 2015;145(7):1507-14.
- 47. Allen LH, Hampel D, Shahab-Ferdows S, York ER, Adair LS, Flax VL, et al. Antiretroviral therapy provided to HIV-infected Malawian women in a randomized trial
- diminishes the positive effects of lipid-based nutrient supplements on breast-milk B vitamins.
  Am J Clin Nutr. 2015;102(6):1468-74.
- 48. Pérez-López FR, Pilz S, Chedraui P. Vitamin D supplementation during pregnancy: an
  overview. Current Opinion in Obstetrics and Gynecology. 2020;32(5):316-21.
- 49. Organization WH. Food and agriculture organization of the United Nations. Vitamin
  and mineral requirements in human nutrition. 2004;2:17-299.
- 816 50. Neufingerl N, Eilander A. Nutrient Intake and Status in Adults Consuming Plant-Based
  817 Diets Compared to Meat-Eaters: A Systematic Review. Nutrients. 2021;14(1).
- 818 51. Hobbs DA, Durrant C, Elliott J, Givens DI, Lovegrove JA. Diets containing the highest
- 819 levels of dairy products are associated with greater eutrophication potential but higher nutrient
- intakes and lower financial cost in the United Kingdom. European journal of nutrition.
  2020;59(3):895-908.

### 823 Table 1. Participant characteristics

		Drasar	antian	Baseline and late		
		Precon	ception	pregnancy <sup>+</sup>		
Characteristic		Control	Intervention	Control	Intervention	
		(n=857)	(n=870)	(n=287)	(n=293)	
Sociodemographic						
Study site	UK	229 (26.7%)	232 (26.7%)	92 (32.1%)	97 (33.1%)	
	Singapore	328 (38.3%)	332 (38.2%)	82 (28.6%)	84 (28.7%)	
	New Zealand	300 (35.0%)	306 (35.2%)	113 (39.4%)	112 (38.2%)	
Age, years	Mean (SD)	30.6 (3.7)	30.6 (3.7)	30.2 (3.3)	30.5 (3.4)	
Ethnicity	White	396 (46.2%)	413 (47.5%)	165 (57.5%)	179 (61.1%)	
	Chinese	220 (25.7%)	238 (27.4%)	73 (25.4%)	72 (24.6%)	
	South Asian	60 (7.0%)	61 (7.0%)	15 (5.2%)	15 (5.1%)	
	Malay	85 (9.9%)	80 (9.2%)	12 (4.2%)	11 (3.8%)	
	Other	96 (11.2%)	78 (9.0%)	22 (7.7%)	16 (5.5%)	
Household income <sup>#</sup>	Low income	74 (9.3%)	76 (9.4%)	11 (4.0%)	12 (4.3%)	
	Middle income	344 (43.2 %)	354 (43.7%)	114 (41.2%)	114 (40.9%)	
	High income	378 (47.5%)	380 (46.9%)	152 (54.9%)	153 (54.8%)	
Gynecological						
Parity	Nulliparous	593 (69.2%)	578 (66.4%)	196 (68.3%)	169 (57.7%)	
	Parous	264 (30.8%)	292 (33.6%)	91 (31.7%)	124 (42.3%)	
Lifestyle						
Alcohol intake (per	Nona	271 (21 60/)	265 (20 59/)	61 (21 20/)	65 (22 20/)	
week)	INOILE	271 (51.070)	203 (30.376)	01 (21.570)	03 (22.270)	
	$>0$ to $\leq 2.5$ units	312 (36.4%)	301 (34.6%)	115 (40.1%)	109 (37.2%)	
	>2.5 units	274 (32.0%)	304 (34.9%)	111 (38.7%)	119 (40.6%)	
Smoking status	Never	664 (77.7%)	662 (76.3%)	225 (78.7%)	237 (80.9%)	
	Previous	131 (15.3%)	136 (15.7%)	49 (17.1%)	44 (15.0%)	
	Active	60 (7.0%)	70 (8.1%)	12 (4.2%)	12 (4.1%)	
Instances of moderate /vigorous physical activity in past 7 days	Median (IQR)	3 (2, 5)	3 (1, 5)	4 (2, 6)	3 (2, 5)	
Body mass index (BMI) category <sup>##</sup>	Not overweight or obese	400 (46.7%)	432 (49.8%)	158 (55.1%)	163 (55.8%)	
	Overweight	240 (28.0%)	224 (25.8%)	69 (24.0%)	89 (30.5%)	
	Obese	216 (25.2%)	212 (24.4%)	60 (20.9%)	40 (13.7%)	
Days between preconception baseline and post-supplementation sampling	Median (IQR)	28 (23, 31)	28 (23, 32)	27 (22, 31)	28 (23, 31)	

B24 Data presented as number (%) unless otherwise stated. Sample sizes do not always equal to

825 857/251 for control group and 870/261 for intervention group due to missing values; <sup>+</sup> based

on all available data for individuals with any analyte at both baseline and late pregnancy

<sup>#</sup>Low 1<sup>st</sup>-3<sup>rd</sup> decile, Middle 4<sup>th</sup>-7<sup>th</sup> decile, High 8<sup>th</sup>-10<sup>th</sup> decile; <sup>##</sup>BMI categories - Not

828 overweight or obese, Overweight and Obese <25, 25-<30 and  $\ge 30$  kg/m<sup>2</sup>, respectively

829 Abbreviations: IQR, interquartile range; SD, standard deviation

	Preconception baseline		Preconception supplen	n 1-month post nentation	Early pr (7-11 week	Early pregnancyLate pregnancy(7-11 weeks gestation)(28 weeks gestation)		6 months post-delivery		
	Controls	Intervention	Controls	Intervention	Controls	Intervention	Controls	Intervention	Controls	Intervention
Folate	22.5	20.5	41.9	40.3	49.8	52.2	41.5	44.1	19.2	18.9
(nmol/L)	(12.7, 41.3)	(12.1, 41.3)	(29.3, 55.0)	(29.0, 52.8)	(40.5, 60.0)	(43.2, 63.0)	(30.6, 51.6)	(34.3, 54.5)	(11.9, 32.7)	(12.3, 32.2)
Homocysteine	7.0	7.1	6.9	6.4	5.5	4.9	4.6	3.9	7.4	7.2
(µmol/L)	(6.1, 8.4)	(6.1, 8.5)	(6.0, 8.0)	(5.6, 7.4)	(4.8, 6.4)	(4.2, 5.6)	(3.9, 5.2)	(3.5, 4.6)	(6.4, 9.0)	(6.1, 8.5)
Riboflavin	12.7	12.0	12.7	24.7	10.7	20.0	10.3	16.9	12.9	12.7
(nmol/L)	(7.7, 21.7)	(7.6, 21.2)	(8.3, 22.3)	(16.7, 36.8)	(6.8, 18.0)	(13.0, 30.3)	(6.6, 15.1)	(12.2, 23.3)	(8.8, 21.1)	(8.4, 22.6)
FMN	14.4	14.6	15.6	18.4	14.5	17.2	10.1	11.5	14.2	14.4
(nmol/L)	(11.5, 18.7)	(11.9, 18.7)	(12.4, 20.1)	(15.0, 23.4)	(11.4, 18.2)	(14.3, 21.6)	(8.4, 12.0)	(9.8, 13.4)	(11.8, 17.0)	(11.2, 18.7)
Pyridoxal 5- phosphate (nmol/L)	55.8 (40.3, 88.4)	57.1 (41.1, 84.3)	56.9 (43.0, 80.1)	140.0 (102.0, 184.0)	47.6 (34.3, 64.1)	106.0 (76.0, 139.0)	19.1 (14.7, 28.1)	41.9 (30.3, 56.4)	56.3 (40.0, 88.2)	56.1 (40.5, 86.6)
HK ratio	0.35	0.36	0.35	0.29	0.35	0.29	0.51	0.44	0.40 (0.32, 0.49)	0.39
(no units)	(0.29, 0.43)	(0.29, 0.42)	(0.29, 0.42)	(0.24, 0.35)	(0.28, 0.43)	(0.24, 0.33)	(0.41, 0.60)	(0.37, 0.54)		(0.32, 0.47)
Cobalamin	355.2	350.9	358.9	438.2	307.4	411.1	214.6	298.7	340.4	385.6
(pmol/L)	(283.1, 434.1)	(278.8, 437.7)	(284.0, 449.3)	(353.3, 552.1)	(240.2, 384.0)	(332.0, 509.3)	(177.3, 270.0)	(247.9, 379.5)	(264.5, 437.8)	(312.3, 465.7)
MMA (µmol/L)	0.13 (0.11, 0.17)	0.13 (0.11, 0.17)	0.15 (0.12, 0.19)	0.15 (0.12, 0.19)	0.12 (0.10, 0.15)	0.11 (0.10, 0.14)	0.14 (0.11, 0.20)	0.12 (0.10, 0.15)	0.15 (0.12, 0.20)	0.14 (0.12, 0.17)
Vitamin D3	51.0	50.1	51.7	61.1	53.3	69.6	62.9	92.8	62.5	64.6
(nmol/L)	(36.0, 65.3)	(36.1, 65.8)	(37.0, 65.5)	(51.1, 73.3)	(41.8, 69.5)	(57.3, 81.2)	(41.0, 87.5)	(73.0, 106.9)	(45.3, 77.6)	(48.5, 77.6)

## 830 Table 2: Median (IQR) values in original units according to control or intervention group at each time-point

831

832 HK ratio – 3'-hydroxykynurenine ratio, FMN – flavin mononucleotide, MMA – methylmalonic acid

34

# 833 Table 3: Percentages of participants meeting vitamin/vitamer deficiency/insufficiency thresholds according to time-point and control/

834	intervention group.	Values in parentheses are 95%	confidence intervals.	*Chi-squared P<	0.05 for intervention vs c	ontrol difference at that time point
-----	---------------------	-------------------------------	-----------------------	-----------------	----------------------------	--------------------------------------

	Preconception baseline		Preconcepti post supple	conception 1-monthEarly pregnancyLate pregnancyost supplementation(7-11 weeks gestation)(28 weeks gestation)		egnancy gestation)	6 months post-delivery			
	Controls	Intervention	Controls	Intervention	Controls	Intervention	Controls	Intervention	Controls	Intervention
Folate	28.1%	30.4%	4.1%	3.6%	1.0%	0.6%	6.1%	3.5%	31.8%	32.9%
<13.6 nmol/L	[25.0, 31.3]	[27.3, 33.7]	[2.8, 5.9]	[2.4, 5.2]	[0.2, 2.8]	[0.1, 2.2]	[3.6, 9.6]	[1.7, 6.3]	[25.9, 38.1]	[27.2, 39.1]
Homocysteine	0.9%	0.8%	0.7%	0.1%	0.0%	0.0%	0.0%	0.0%	0.4%	2.3%
≥15 µmol/L	[0.4, 1.8]	[0.3, 1.7]	[0.2, 1.6]	[0.0, 0.7]	[0.0, 1.2]	[0.0, 1.1]	[0.0, 1.3]	[0.0, 1.3]	[0.0, 2.2]	[0.8, 4.9]
Riboflavin	7.3%	7.7%	6.2%	0.4%*	12.5%	0.9%*	12.8%	2.7%*	4.0%	3.4%
<5 nmol/L	[5.6, 9.2]	[6.0, 9.7]	[4.6, 8.3]	[0.1, 1.2]	[9.0, 16.7]	[0.2, 2.6]	[9.2, 17.3]	[1.2, 5.3]	[1.9, 7.2]	[1.6, 6.4]
Riboflavin	81.1%	82.8%	80.3%	56.1%*	85.6%	66.9%*	92.4%	81.9%*	82.5%	82.8%
≤26.5 nmol/L	[78.4, 83.7]	[80.1, 85.3]	[77.2, 83.2]	[52.4, 59.7]	[81.1, 89.3]	[61.5, 71.9]	[88.7, 95.2]	[77.0, 86.1]	[77.2, 87.0]	[77.6, 87.1]
Pyridoxal 5-phosphate <20 nmol/L	0.8%	1.8%	0.1%	0.4%	2.6%	0.0%*	54.2%	10.2%*	1.2%	0.8%
	[0.3, 1.7]	[1.1, 3.0]	[0.0, 0.8]	[0.1, 1.2]	[1.1, 5.1]	[0.0, 1.1]	[48.2, 60.0]	[7.0, 14.3]	[0.2, 3.5]	[0.1, 2.7]
Cobalamin	0.6%	0.5%	0.6%	0.0%	1.6%	0.3%	11.1%	4.8%*	0.8%	0.4%
<148 pmol/L	[0.2, 1.4]	[0.1, 1.2]	[0.2, 1.4]	[0.0, 0.5]	[0.5, 3.8]	[0.0, 1.7]	[7.7, 15.3]	[2.6, 7.9]	[0.1, 2.9]	[0.0, 2.1]
Cobalamin	7.5%	10.8%*	7.0%	2.4%*	18.1%	3.7%*	55.2%	16.7%*	12.4%	5.4%*
<221 pmol/L	[5.8, 9.5]	[8.8, 13.0]	[5.2, 9.1]	[1.4, 3.8]	[13.9, 22.9]	[1.9, 6.3]	[49.3, 61.0]	[12.6, 21.5]	[8.6, 17.1]	[3.0, 8.8]
MMA	6.2%	8.7%	8.5%	8.6%	7.5%	3.6%*	11.8%	5.8%*	10.0%	5.4%
>0.26 μmol/L	[4.7, 8.0]	[6.9, 10.7]	[6.5, 10.8]	[6.7, 10.8]	[4.8, 11.1]	[1.9, 6.3]	[8.3, 16.1]	[3.4, 9.1]	[6.5, 14.4]	[3.0, 8.8]
Vitamin D3	47.7%	49.7%	47.5%	22.0%*	43.0%	12.2%*	35.1%	8.5%*	30.7%	27.2%
<50 nmol/L	[44.3, 51.1]	[46.3, 53.1]	[43.8, 51.3]	[19.0, 25.1]	[37.3, 48.7]	[8.8, 16.2]	[29.6, 40.9]	[5.6, 12.3]	[25.0, 36.8]	[21.9, 33.0]
Vitamin D3	85.7%	85.0%	85.1%	78.2%*	82.3%	65.7%*	64.6%	27.3%*	70.5%	70.5%
<75 nmol/L	[83.2, 88.0]	[82.5, 87.3]	[82.3, 87.7]	[75.0, 81.1]	[77.5, 86.4]	[60.2, 70.8]	[58.8, 70.1]	[22.3, 32.8]	[64.5, 76.1]	[64.6, 76.0]

835

## 836 MMA - methylmalonic acid



Figure 1: Plasma folate, marginal folate status and plasma homocysteine according to
 time-point and control vs intervention group















869 Supplementary Figure 1. Flowchart of study participants from assessment of eligibility,

870 through randomization, conception, pregnancy and post-delivery. Abbreviation: Cesarean,

#### 871 cesarean section delivery.



\*Randomised - 607 New Zealand, 661 Singapore, 461 United Kingdom

<sup>+</sup>Pregnancies before study visit 2 which occurred 3-6 weeks after recruitment were excluded as the intervention was postulated to have inadequate time to have the desired effect for the pregnancy.

"Premature ovarian failure; ## new onset Graves' disease, hemoglobinopathy with iron overload, prolactinoma, endometrial polyp, endometrial atypia, breast cancer.

<sup>&</sup> Withdrew as product may contain animal remnants, no storage space, participant perception of product-related symptoms. <sup>S</sup>Includes one neonatal death



#### Supplementary Figure 2. Marginal riboflavin status (plasma riboflavin ≤26.5 nmol/L)

Supplementary Figure 3. Plasma cystathionine/cysteine ratio





#### Supplementary Figure 4. Vitamin B12 deficiency (<148 pmol/L) 878

879

880	Supplementary Table 1: Median (IQR) values in original units according to control or intervention group at each time-point, for
881	participants with measurements at each of preconception baseline and late pregnancy

	Preconception baseline		Preconception supplen	n 1-month post nentation	Early pr (7-11 week	regnancy as gestation)	Late pro (28 weeks	egnancy gestation)	6 months post-delivery	
	Controls (n=287)	Intervention (n=293)	Controls (n=286)	Intervention (n=292)	Controls (n=276)	Intervention (n=289)	Controls (n=287)	Intervention (n=293)	Controls (n=247)	Intervention (n=260)
Folate	23.1	23.8	44.4	42.9	49.9	52.2	41.5	44.1	19.3	19.0
(nmol/L)	(13.5, 41.3)	(13.6, 42.6)	(30.9, 56.3)	(31.4, 54.2)	(40.6, 60.2)	(43.7, 63.0)	(30.6, 51.4)	(34.3, 54.5)	(11.9, 33.2)	(12.4, 32.4)
Homocysteine	7.0	7.1	6.8	6.3	5.5	4.8	4.6	3.9	7.4	7.2
(µmol/L)	(6.1, 8.3)	(6.0, 8.4)	(6.0, 7.9)	(5.5, 7.3)	(4.8, 6.4)	(4.2, 5.5)	(3.9, 5.2)	(3.5, 4.6)	(6.4, 9.0)	(6.1, 8.5)
Riboflavin	12.7	13.7	12.6	25.1	10.8	19.7	10.2	16.9	13.0	12.8
(nmol/L)	(7.5, 19.6)	(8.6, 21.3)	(8.4, 21.5)	(16.8, 38.0)	(6.7, 18.4)	(13.0, 29.8)	(6.6, 15.1)	(12.2, 23.3)	(8.9, 21.1)	(8.4, 22.6)
FMN	14.7	15.0	15.6	19.0	14.3	17.4	10.1	11.5	14.2	14.4
(nmol/L)	(11.4, 18.7)	(12.0, 19.6)	(12.7, 19.5)	(15.1, 25.1)	(11.4, 18.3)	(14.2, 21.6)	(8.4, 12.0)	(9.8, 13.4)	(11.8, 17.0)	(11.2, 18.7)
Pyridoxal 5- phosphate (nmol/L)	59.4 (42.4, 92.1)	61.0 (44.9, 99.0)	57.2 (44.7, 79.3)	144 (107, 187)	47.6 (34.7, 64.2)	104.0 (75.8, 138.0)	19.2 (14.6, 28.3)	41.9 (30.3, 56.4)	55.9 (40.0, 88.1)	56.4 (40.5, 86.8)
HK ratio	0.35	0.36	0.36	0.29	0.35	0.29	0.51	0.44	0.40	0.39
(no units)	(0.30, 0.43)	(0.30, 0.41)	(0.29, 0.42)	(0.26, 0.34)	(0.28, 0.42)	(0.24, 0.33)	(0.41,0.61)	(0.37,0.54)	(0.32, 0.49)	(0.32, 0.47)
Cobalamin	355	354	355	447	307	411	214	299	342	386
(pmol/L)	(276, 444)	(278, 434)	(278, 449)	(357, 553)	(240, 385)	(332, 511)	(176, 270)	(248, 380)	(265, 438)	(312, 466)
MMA	0.13	0.14	0.15	0.15	0.12	0.11	0.14	0.12	0.15	0.14
(µmol/L)	(0.11, 0.17)	(0.11, 0.18)	(0.12, 0.21)	(0.12, 0.19)	(0.10, 0.15)	(0.10, 0.14)	(0.11,0.20)	(0.10,0.15)	(0.12, 0.20)	(0.12, 0.17)
Vitamin D3	53.5	54.4	54.4	64.8	52.8	70.0	62.9	92.8	62.3	65.1
(nmol/L)	(40.3, 68.0)	(39.6, 70.0)	(40.5, 69.4)	(54.5, 76.4)	(41.5, 69.4)	(57.6, 81.8)	(41.0, 87.5)	(73.0,106.9)	(45.3, 77.6)	(48.4, 78.2)

882 HK ratio – 3'-hydroxykynurenine ratio, FMN – flavin mononucleotide, MMA - methylmalonic acid